Boston, MA -- (SBWIRE) -- 07/20/2012 -- Peptides are an important class of drugs, but their potential for treating chronic diseases will be fully realized only if more acceptable delivery methods than daily injections can be developed. Recognition of this has led to advances in oral, intranasal, inhaled, transdermal, and buccal formulations. This report analyses the products and companies at the forefront of such research.
- Assess the breadth of innovations that have been applied to the delivery of peptide drugs.
- Compare the various technologies developed for use within particular indications.
- Evaluate the merits and limitations of each company's peptide delivery solutions.
- Gain insight from analysis of the patents filed to protect specific delivery technologies.
- Understand the technical principles on which the delivery technologies are based.
View Full Report Details and Table of Contents
The demise of Exubera, an inhaled insulin product, has had a knock-on effect on the inhaled insulin technologies and there are now few still in development, despite products offering strong advantages such as fast absorption, fast onset of action, and a non-invasive mode of administration.
New oral nanotechnology peptide formulations are showing promise, particularly in the area of insulin and GLP-1 analog delivery. New long-acting peptides and controlled release injectable formulations are extending peptide half-lives significantly, leading to weekly and even monthly subcutaneous injectable formulations.
First- and second-generation transdermal patch technologies were not suitable for peptide drug delivery due to the need for low molecular weight and low dose loading, but third-generation patch technologies (such as thermal ablation, microneedles, vesicular carriers, and iontophoresis) are offering promise in the delivery of several peptides
Reasons to Get this Report
- What type of delivery technologies are available to those developing peptide therapeutics?
- What peptide delivery challenges are the innovations intended to overcome?
- Which indications offer the greatest advances by investment in delivery technologies?
- Which companies have already formed partnerships with the inventors of cutting-edge delivery techniques?
- What hurdles remain for specific technologies and how far are they from being employed in a commercialized drug?
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth
- Drug Delivery Innovations Driving Improved Patient Compliance
- Collection Point Strategies in European Retail: Click and Collect Innovations Driving Online Spend
- Alere Inc. Market Share Analysis
- Anesthesia Machines in BRICS Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
- Insulin Delivery Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
- Drug Delivery Devices Market Outlook in United States to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
- UK Home Delivery 2011
- The Future of Content Delivery
- Small Bone Innovations, Inc. - Medical Equipment - Deals and Alliances Profile